REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Bioextra Zrt. (Hungary)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: BIOEXTRA Zrt. Profile Updated: July 26, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Hungarian Download a sample report

Bioextra is a dietary supplement company that offers a range of products to support customer health. Bioextra's product line includes grapefruit seed extract, vitamin D3 supplements, herbal extract drops, and dietary supplement capsules, catering to various health needs such as liver regeneration, blood formation, and iron deficiency in babies.

Headquarters
Vaci ut 33.
Budapest; Budapest; Postal Code: 1134

Contact Details: Purchase the Bioextra Zrt. report to view the information.

Website: http://www.bioextra.hu

Basic Information
Total Employees:
Purchase the Bioextra Zrt. report to view the information.
Outstanding Shares:
Purchase the Bioextra Zrt. report to view the information.
Registered Capital:
Purchase the Bioextra Zrt. report to view the information.
Financial Auditors:
Purchase the Bioextra Zrt. report to view the information.
Incorporation Date:
April 01, 2009
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Ownership Details
Purchase this report to view the information.
Purchase this report to view the information.
Purchase this report to view the information.
Subsidiaries
Recyclomed Nonprofit Kft.
Company Performance
Financial values in the chart are available after Bioextra Zrt. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency HUF. Absolute financial data is included in the purchased report.
Net sales revenue
-2.38%▼
Total operating revenue
-2.07%▼
Operating profit (EBIT)
-81.23%▼
EBITDA
-62.78%▼
Net Profit (Loss) for the Period
-90.17%▼
Total assets
-12.79%▼
Total equity
-28.07%▼
Operating Profit Margin (ROS)
-13.68%▼
Net Profit Margin
-14.68%▼
Return on Equity (ROE)
-26.91%▼
Debt to Equity Ratio
9.1%▲
Quick Ratio
-0.08%▼
Cash Ratio
-0.25%▼

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo